News Wire ~ 3rd Party Press Release


FDA Warns About Serious Health Problems with High Doses of Benadryl

Teen misuse sparked by dangerous “Benadryl Challenge” promoted on social media.
Cells in Culture

Research Links the Hormones You’re Born with to Lifetime Risk for Immunological Diseases

Study answers questions about why females are at increased risk for common diseases that involve or target the immune system like asthma, allergies, migraines and irritable bowel syndrome.
Classroom During Pandemic

AAAAI and NASN Release Guidance on Managing Food Allergies in Schools During COVID-19

New document addresses specific food processes, anaphylaxis treatment, and additional safety considerations for schools during COVID-19 to keep students with food allergies safe.
FARE 2020 Living Teal Summit

FARE Announces Living Teal™ Global Summit Speaker Lineup

Diverse roster of speakers and influencers to cover wide range of topics, reach new audiences, expand awareness of food allergies.
Fall Baby

Study Finds Fall Babies at Higher Risk of Lifetime of Allergic Diseases

Children born in the fall were much more likely to experience all of the conditions associated with the atopic march.
2020 Contains Courage Research Retreat

FARE Announces 2020 Contains: Courage® Research Retreat

Virtual two-day event to feature guest appearance by Dr. Anthony Fauci and sessions open to public for the first time ever.
Nestle Acquires Aimmune

Nestlé to Acquire Aimmune Therapeutics

Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
Aquestive AQST-108 Epinephrine Film

Aquestive’s Sublingual Epinephrine Film Receives FDA Fast Track Designation for Treatment of Anaphylaxis

First planned PK clinical trial expected to begin during the third quarter of 2020.

Kaleo Announces Public and Private Insurance Plans to Cover Allerject, the Canadian Version of...

Ontario and Quebec public drug plans are first to list ALLERJECT with other provinces expected to follow soon.